Sophiris Bio Inc. Reports Third Quarter Financial Results And Recent Key Operational Highlights
Published: Nov 13, 2013
Sophiris Bio Inc. (Sophiris, NASDAQ: SPHS, TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and nine months ended September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.